SCHEMBL8477148

SCHEMBL8477148

CCCCCCCCN1CCC2(C1)OC(OC)Cc1ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8487170 0.96 ADRA2A (0.69) SIGMAR1
SCHEMBL4181419 0.94 — —
SCHEMBL4323053 0.94 — —
SCHEMBL4181417 0.94 — —
SCHEMBL8473828 0.94 — —
SCHEMBL8475042 0.94 — —
SCHEMBL4191289 0.94 — —
SCHEMBL8473494 0.94 — —
SCHEMBL4184105 0.94 — —
SCHEMBL5268819 0.94 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038287-B1 SPIRO[BENZOPYRAN]OR SPIRO[BENZOFURAN]DERIVATIVES WHICH INHIBIT THE SIGMA RECEPTOR ESTEVE LABOR DR (ES) 2012-12-26 — — EP disclosed
US-20090209568-A1 Spiro [Benzopyran] or Spiro [Benzofuran] Derivatives Which Inhibit the Sigma Receptor LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2009-08-20 — — US disclosed
US-20090209568-A1 Spiro [Benzopyran] or Spiro [Benzofuran] Derivatives Which Inhibit the Sigma Receptor LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2009-08-20 — — US disclosed
WO-2007121976-A1 SPIRO[BENZOPYRAN] OR SPIRO[BENZOFURAN] DERIVATIVES WHICH INHIBIT THE SIGMA RECEPTOR LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) 2007-11-01 — — WO disclosed
EP-1847542-A1 Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor Laboratorios del Dr. Esteve S.A. (ES) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209568-A1 Spiro [Benzopyran] or Spiro [Benzofuran] Derivatives Which Inhibit the Sigma Receptor SIGMAR1, TMEM97, OPRD1 SIGMAR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback